睿知中国医院研究地图
候选清单

即将招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由中国医学科学院肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT04736589,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 85 岁;性别:仅女性

    登记记录的入选字段

  2. Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease.

    入选标准第 3 条

  3. Patients with HER2-positive metastatic breast cancer who have progressed disease after trastuzumab treatment include the following four types of patients (Note: The following patients are in a parallel relationship):

    入选标准第 4 条

    Patients with HER2-positive breast cancer who have progressed during adjuvant trastuzumab treatment after surgery; or

    入选标准第 5 条

    Patients with HER2-positive breast cancer who have relapsed or metastasized after receiving adjuvant trastuzumab therapy; or

    入选标准第 6 条

    HER2-positive recurrent or metastatic BC patients who have progressed after receiving at least 4 weeks of trastuzumab as first-line treatment ; or

    入选标准第 7 条

    HER2-positive metastatic BC patients who have never been treated have progressed after receiving at least 4 weeks of trastuzumab as first-line treatment.

    入选标准第 8 条

  4. ECOG PS score ≤2, estimated survival time ≥6 months, and can be followed-up;

    入选标准第 10 条

  5. Total bilirubin ≤ 1.5 times the upper limit of normal value. Patients with known Gibert's disease can be included in the group if combined bilirubin ≤ 1.5 times the upper limit of normal value;

    入选标准第 14 条

    AST and ALT ≤2.5 times the upper limit of the normal value; if there is liver metastasis, ≤5 times the upper limit of the normal value (the normal value is the normal value specified by this clinical trial center);

    入选标准第 15 条

    ANC≥1.5 x 10\^3 /μL;

    入选标准第 17 条

    Hemoglobin ≥9 g/dL.

    入选标准第 19 条

  6. Patients with measurable disease as per RECIST 1.1 criteria;

    入选标准第 11 条

  7. Hepatitis B or hepatitis C carriers, or other known chronic liver diseases; HIV positive;

    排除标准第 7 条

    Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma;

    排除标准第 11 条

  8. Female patients of childbearing age have a negative pregnancy test and voluntarily take effective and reliable contraceptive measures;

    入选标准第 22 条

    Women during pregnancy or lactation;

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04736589,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Female, Aged > 18;
  2. HER2-positive breast cancer are defined as immunohistochemical (IHC) testing as +++, or IHC++ with FISH testing of positive;
  3. Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease.
  4. Patients with HER2-positive metastatic breast cancer who have progressed disease after trastuzumab treatment include the following four types of patients (Note: The following patients are in a parallel relationship):
  5. Patients with HER2-positive breast cancer who have progressed during adjuvant trastuzumab treatment after surgery; or
  6. Patients with HER2-positive breast cancer who have relapsed or metastasized after receiving adjuvant trastuzumab therapy; or
  7. HER2-positive recurrent or metastatic BC patients who have progressed after receiving at least 4 weeks of trastuzumab as first-line treatment ; or
  8. HER2-positive metastatic BC patients who have never been treated have progressed after receiving at least 4 weeks of trastuzumab as first-line treatment.
  9. Genetic testing shows that the PI3K/Akt/mTOR pathway related genes are mutated;
  10. ECOG PS score ≤2, estimated survival time ≥6 months, and can be followed-up;
  11. Patients with measurable disease as per RECIST 1.1 criteria;
  12. Cardiopulmonary function is basically normal, LVEF≥50% within 4 weeks before starting treatment;
  13. An adequate liver function with the following definition:
  14. Total bilirubin ≤ 1.5 times the upper limit of normal value. Patients with known Gibert's disease can be included in the group if combined bilirubin ≤ 1.5 times the upper limit of normal value;
  15. AST and ALT ≤2.5 times the upper limit of the normal value; if there is liver metastasis, ≤5 times the upper limit of the normal value (the normal value is the normal value specified by this clinical trial center);
  16. Have sufficient baseline hematology parameters, defined as follows:
  17. ANC≥1.5 x 10\^3 /μL;
  18. Platelet count ≥100 x 10\^3/μL, if it is 75-100 x 10\^3/μL, it may be included in the group, as long as the doctors believe it can be included;
  19. Hemoglobin ≥9 g/dL.
  20. Coagulation Indicators: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 times the upper limit of normal, unless drugs known to change INR and aPTT are used;
  21. No history of serious heart, kidney and other important organs and endocrine disease;
  22. Female patients of childbearing age have a negative pregnancy test and voluntarily take effective and reliable contraceptive measures;
  23. The patients voluntarily signed an informed consent form.

排除标准:Exclusion Criteria:

  1. Participated in other clinical trials within 4 weeks;
  2. Have used mTOR inhibitors in the past;
  3. Previous use of Pyrotinib in first-line treatment stage; previous use of lapatinib is allowed;
  4. Accompanied by immunosuppressant or chronic corticosteroid medication, or more than 25% bone marrow radiotherapy within 4 weeks;
  5. Symptomatic CNS metastases or evidence of leptomeningeal disease;
  6. Gastrointestinal dysfunction or gastrointestinal diseases (including active ulcers);
  7. Hepatitis B or hepatitis C carriers, or other known chronic liver diseases; HIV positive;
  8. Known hypersensitivity to any study medication
  9. Women during pregnancy or lactation;
  10. Left ventricular ejection fraction <50%; clinical manifestations of patients with obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency, and severe valvular disease;
  11. Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma;
  12. The researchers decide that any other medical, social or psychological conditions which are inappropriate to participate in this trial.

引自 ClinicalTrials.gov, NCT04736589, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04736589,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT04736589